Skip to main content
OpenTrials
Completed

NCT Number: NCT05909774

Assessment of the Interest of the Atalante Device for Patients With Manual Wheelchairs

The loss of standing and walking capabilities in a paraplegic person is most often the result of damage to the spinal cord, either traumatic (accidental) or pathological and has both a somatic and a psychological impact on the quality of life, the risk of depression, and the difficulty of socio-professional reintegration in a society that is not adapted to people with disabilities.

A motorized mechanical exoskeleton is an external device intended to compensate for a muscular or neurological deficiency enabling paraplegics to stand and walk again. The Atalante exoskeleton, designed by Wandercraft company allows patients to stand upright and walk without the aid of crutches.

This early study was the first clinical investigation of the Atalante exoskeleton performed early in the development. It was used to evaluate the device design concept with respect to initial clinical safety and device functionality and guided further device modifications.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CEREMH (Centre de ressources et d'innovation mobilité handicap)

Vélizy-Villacoublay, 78140, France

About this study

The aim of this study was to test the use of the Atalante exoskeleton on 10 patients with complete motor paraplegia (ASIA A and B) with a level of injury between T6 and S1.

In this multi-centric clinical trial, patients were asked to perform between 1 and 2 days of training with Atalante exoskeleton including device training and evaluations (up to 9 hours of training and 3 hours of evaluation per patient).

The primary objective of this study was to assess patients' ability to walk straight- for 10 meters with the Atalante exoskeleton during 10-meters walk test (10MWT).

Within-group differences between the Atalante exoskeleton and the usual walking aid used by the patient in the success rate of the 10MWT were compared by a McNemar test.

The secondary objectives focused on performance evaluation with the Atalante exoskeleton. The assessments performed were:

  • Assessment of the superiority of the Atalante exoskeleton compared to the usual aid walking assistance used by the patient on the walking, verticalization (or sit-to-stand), static and dynamic balance ability
  • Assessment of the static and dynamic postural stability of the subject with the Atalante exoskeleton by observation of center of pressure displacement and velocity
  • Assessment of the perceived effort by the patient
  • Assessment of perceived safety by the patient
  • Assessment of the overall satisfaction of patients after using the exoskeleton
  • Comparison of the two types of walk on walking ability, perceived effort, and safety

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Under 60 years of age
  • Daily and autonomous use of wheelchair
  • Paraplegia with level of injury between T6 and S1
  • Patient unable to walk, neither during physiotherapy session nor in a daily routine
  • Patient with cognitive capacities: able to understand oral and/or written instructions, as well as instructions given by demonstration
  • Able to use their upper limbs
  • Can be verticalized
  • Patient with a health care insurance
  • Patient having given his/her written consent
  • Joints amplitudes compatible with the use of the exoskeleton:
  • Hip: Flexion>115°; Extension>15°; Abduction>17°; Adduction >10°; Medial rotation>35°; Internal rotation>10°
  • Knee: Flexion>105°; Extension> -5°
  • Ankle: Flexion>0°; Extension>9°; Supination>18°; Pronation>18°

Exclusion criteria

  • Severe or complete deficiency of the upper limbs
  • Bad control of the trunk
  • Vestibular disorder (loss of balance, dizziness, …) when placed in the vertical position
  • Upper limbs involuntary shivers and/or movements
  • Pregnant women
  • A lower or upper limb amputated
  • Epilepsy
  • Patient carrying an active implantable medical device

Treatment and study plan

Test with Atalante exoskeleton in "continuous walk" type

Device

The "continuous" walk is smoother and more physiologic than the "push and swing" walk

Other names: Test with Atalante exoskeleton in "push and swing" walk type

Primary outcomes

  1. The primary objective of this study was to assess patients' ability to walk straight- for 10 meters with the Atalante exoskeleton during 10-meters walk test (10MWT).

    Time frame: Day 2

    Within-group differences between the Atalante exoskeleton and the usual walking aid used by the patient in the success rate of the 10MWT were compared by a McNemar test.

Secondary outcomes

  1. Assessment of the superiority of the Atalante exoskeleton compared to the usual aid

    Time frame: Day 2

    Evaluation of walking ability through a 10mWT

  2. Assessment of the superiority of the Atalante exoskeleton compared to the usual aid

    Time frame: Day 2

    Evaluation of verticalization ability through a success/failure test in a verticalization test (sit-to-stand movement)

  3. Assessment of the superiority of the Atalante exoskeleton compared to the usual aid

    Time frame: Day 2

    Evaluation of static balance through a success failure in a static standing test without support from the operator (3 x 30s in a static standing position)

  4. Assessment of the superiority of the Atalante exoskeleton compared to the usual aid

    Time frame: Day 2

    Evaluation of dynamic balance through a success/failure in a pointing test performed in a standing position without support from the operator (3 pointing sequences)

  5. Assessment of the static and dynamic postural stability

    Time frame: Day 2

    Static balance test with measurement of center of pressure displacement

  6. Assessment of the static and dynamic postural stability

    Time frame: Day 2

    Dynamic balance test with measurement of the average surface area under the (Center of Pressure position, Center of Pressure velocity) curve

  7. Assessment of the perceived effort by the patient

    Time frame: Day 2

    Evaluation of perceived effort by the patient through a Borg CR-10 scale

  8. Assessment of perceived safety by the patient

    Time frame: Day 2

    Evaluation of perceived safety by the patient through a 7-point Likert scale

  9. Assessment of the overall satisfaction of patients after using the exoskeleton

    Time frame: Day 2

    Assessment of the patient overall satisfaction through a 7-point Likert scale

  10. Comparison of the two types of walk

    Time frame: Day 2

    Comparison of the two types of walk on walking ability through the 10mWT

  11. Comparison of the two types of walk

    Time frame: Day 2

    Comparison of the two types of walk on perceived effort during the 10mWT through a Borg CR-10 Scale

  12. Comparison of the two types of walk

    Time frame: Day 2

    Comparison of the two types of walk on perceived safety during the 10mWT through a 7-point Likert scale

Sponsors and collaborators

Lead sponsor

Wandercraft

Industry

Registry information

Acronym: M1-M2

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jun 18, 2023
Registry last updated
Jun 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.